A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

Sex: All

Ages: 18 Years – 75 Years

Healthy volunteers: Yes

Phase: PHASE1, PHASE2

Enrollment: 94

Sponsor: Ingenia Therapeutics INC

Summary

The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease. The main question it aims to answer is: Is IGT-303 safe as a single dose or multiple dose regimen when applied under the skin (subcutaneously (SC)) or to a vein (intravenously (IV)). Researchers will compare IGT-303 against a placebo to see if IGT-303 is safe for use. Participants will be assigned to either IGT-303 or placebo and assessed for safety and tolerability for the duration of the study.

Eligibility Criteria

Inclusion Criteria: * Participant 18-75 years of age, inclusive, at Screening; * Able to understand the key components of the study as described in the written informed consent document, and willing and able to provide written informed consent; * Body mass index (BMI) within the range of 18.5 to 40 kg/m2 at Screening; * Have a diagnosis of chronic kidney disease stage 2-3b, resulting from Type 2 diabetic nephropathy; * UACR \>30 mg/g, \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07231679). StuddyBuddy aggregates publicly available trial information.